Oncology Clinical Development, GlaxoSmithKline Inc., 5 Moore Drive, Research Triangle Park, NC 27709, USA.
Acta Oncol. 2011 Jun;50 Suppl 1:127-36. doi: 10.3109/0284186X.2010.527367.
Over the past two decades, many more men are diagnosed with prostate cancer then die of the disease. This increase in diagnosis has led to aggressive treatment of indolent disease in many individuals and has been the impetus for finding a means of reducing the risk of prostate cancer. In the past decade, there have been eight large trials of prostate cancer risk reduction using dietary supplements, 5α-reductase inhibitors, or anti-estrogens. The only two trials which have demonstrated efficacy are those involving 5α-reductase inhibitors: the PCPT (finasteride) and REDUCE (dutasteride). This review examines prostate cancer risk reduction, with emphasis on conclusions that can be drawn from these two landmark studies.
在过去的二十年中，被诊断出患有前列腺癌的男性人数多于死于该病的人数。这种诊断的增加导致许多个体对惰性疾病进行了积极的治疗，这也是寻找降低前列腺癌风险的方法的动力。在过去的十年中，已经进行了八项使用膳食补充剂、5α-还原酶抑制剂或抗雌激素药物来降低前列腺癌风险的大型试验。唯一证明有效的两项试验涉及 5α-还原酶抑制剂：PCPT（非那雄胺）和 REDUCE（度他雄胺）。本综述探讨了前列腺癌的风险降低，重点介绍了从这两项具有里程碑意义的研究中得出的结论。
